Compare Msci Inc (MSCI) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Tilray Brands Inc — how do they compare? Msci Inc trades at $554.53 (market cap $40.09B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Msci Inc is far larger — about 67.8× Tilray Brands Inc's market cap, and Msci Inc pays a 1.49% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| MSCI | TLRY | |
|---|---|---|
Market Cap | $40.09B | $591.60M |
Sector | Financials | Health |
52-Week High | $643.83 | $21.00 |
52-Week Low | $511.84 | $3.88 |
Enterprise Value | $46.25B | $758.73M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent Q2 2026 earnings slightly missed expectations, but the company maintains robust profitability and a $2.05 dividend. Analyst consensus is bullish with a $728.14 price target, though technical indicators suggest near-term pressure with support at $545.
Outlook remains positive driven by high-margin recurring revenue and strategic acquisitions like First Street. Risks include elevated debt levels and market sensitivity. Institutional sentiment is strong with 73% buy ratings, positioning MSCI for long-term growth despite current technical weakness.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
